Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000232349 | SCV000285332 | likely benign | Tuberous sclerosis 2 | 2023-10-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001540412 | SCV001758295 | uncertain significance | not provided | 2021-04-22 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In-silico analysis is inconclusive as to whether the variant alters gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown. |
Genome- |
RCV000232349 | SCV002039714 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002321857 | SCV002607801 | likely benign | Hereditary cancer-predisposing syndrome | 2020-02-19 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV001540412 | SCV004133842 | likely benign | not provided | 2022-03-01 | criteria provided, single submitter | clinical testing | TSC2: BP4, BP7 |
Color Diagnostics, |
RCV000232349 | SCV004360895 | likely benign | Tuberous sclerosis 2 | 2022-09-28 | criteria provided, single submitter | clinical testing |